IBB News and Press, iShares Biotechnology ETF

2026-02-26 06:56:00 ET Optimism builds as positioning evolves Equity managers are navigating a challenging backdrop: concentrated market leadership, wide valuation gaps between U.S. and non-U.S. equities, and policy uncertainty as we move through Q1 2026. AI positioning remains ...

2026-02-18 13:44:55 ET Since my last article in September, " Vertex Pharmaceuticals: Trikafta And Alyftrek Cement Market Leadership ," Vertex Pharmaceuticals Incorporated ( VRTX ) stock is up 25.1%.... Read the full article on Seeking Alpha For further detail...

2026-02-16 13:05:27 ET More on short interest report Most and least shorted mid-to mega-cap healthcare stocks in January Hims & Hers short interest climbs amid legal risk related to weight loss pill HE, OTTR draw highest short interest in utilities sector; BIP an...

2026-02-13 09:35:07 ET More on The Health Care Select Sector SPDR® Fund ETF Big Pharma's Earnings Week: Strong Performance, Obesity Wars, LOE Management And More CMS Rates Proposal Shatters Health Insurance Stocks: What Investors Must Know (& Do) Insurers Br...

2026-02-07 08:15:00 ET Welcome back to my weekly investing-themed variety show! Every week, I seek to understand and explain market trends, especially those relevant to my fellow dividend investors, with the help of interesting and illuminating charts.... Read the full article...

2026-01-29 09:00:00 ET Since my November article , "Pfizer: Is This Pharma Giant Finally A Bargain", Pfizer stock ( PFE ) has risen 5.6%, outperforming the 'barometer' for the biotech investors, the iShares Biotechnology ETF ( IBB ) [5.2% return], as well as the S&P 500 ...

2026-01-28 23:50:00 ET After the run higher in valuations, investors may want to consider smaller, mid-cap stocks for both portfolio diversification and growth potential, according to Brian Dasuch, Portfolio Specialist with T. Rowe Price. ... Read the full article on Seeking A...

2026-01-27 05:10:39 ET After a multi-year drought, the iShares Biotechnology ETF ( IBB ) has been quietly having a fantastic run, returning about 28% for 2025, dwarfing its modest returns in 2023, alongside losses in 2022, 2024, amid a renewed risk appetite, a healthy environment of...

2026-01-26 06:22:39 ET Biotech stocks have stormed back to be among the alpha leaders over the past few quarters. The iShares Biotechnology ETF (IBB) fell hard from Q4 2024 to the April 2025 low, sharply lagging the S&P 500 over that stretch. Since springtime last year, however, i...

2026-01-24 14:20:00 ET The biotech sector returned to health in 2025 after years of sickly returns. A key sign of vitality was the SPDR S&P Biotech ETF (NASDAQ: IBB) , which rose 27% in 2025, nearly doubling the 16% gain by the S&P 500 . Lower interest rates aided th...